PURPOSE: To investigate the efficacy of serial anti-vascular endothelial growth factor injections for choroidal neovascularization associated with choroidal osteoma. METHODS: In this retrospective interventional case series, eyes with choroidal osteoma and associated choroidal neovascularization were treated with intravitreal ranibizumab or bevacizumab with or without photodynamic therapy consolidation. Resolution of subretinal fluid on optical coherence tomography and best-corrected visual acuity were assessed. RESULTS: Eight eyes in eight patients were treated with monthly intravitreal anti-vascular endothelial growth factor injections with or without photodynamic therapy. Resolution of subretinal fluid on optical coherence tomography was achieved in 7 of 8 eyes (87%) with a mean of 12.3 ± 12.6 injections (range, 1-40). Four eyes (50%) experienced at least 1 recurrence of exudation at a mean interval of 10 months (median, 7.5; range, 5-21 months), necessitating further therapy. The mean Snellen visual acuity improvement was 1 ± 4 lines (range, loss 3 to gain 7 lines) at a mean of 32-months follow-up. CONCLUSION: Serial anti-vascular endothelial growth factor therapy alone or with photodynamic therapy consolidation for choroidal neovascularization due to choroidal osteoma resulted in anatomical improvement and modest visual gain.
PURPOSE: To investigate the efficacy of serial anti-vascular endothelial growth factor injections for choroidal neovascularization associated with choroidal osteoma. METHODS: In this retrospective interventional case series, eyes with choroidal osteoma and associated choroidal neovascularization were treated with intravitreal ranibizumab or bevacizumab with or without photodynamic therapy consolidation. Resolution of subretinal fluid on optical coherence tomography and best-corrected visual acuity were assessed. RESULTS: Eight eyes in eight patients were treated with monthly intravitreal anti-vascular endothelial growth factor injections with or without photodynamic therapy. Resolution of subretinal fluid on optical coherence tomography was achieved in 7 of 8 eyes (87%) with a mean of 12.3 ± 12.6 injections (range, 1-40). Four eyes (50%) experienced at least 1 recurrence of exudation at a mean interval of 10 months (median, 7.5; range, 5-21 months), necessitating further therapy. The mean Snellen visual acuity improvement was 1 ± 4 lines (range, loss 3 to gain 7 lines) at a mean of 32-months follow-up. CONCLUSION: Serial anti-vascular endothelial growth factor therapy alone or with photodynamic therapy consolidation for choroidal neovascularization due to choroidal osteoma resulted in anatomical improvement and modest visual gain.
Authors: V P Papastefanou; M Pefkianaki; L Al Harby; A K Arora; V M L Cohen; R M Andrews; M S Sagoo Journal: Eye (Lond) Date: 2016-04-01 Impact factor: 3.775
Authors: Timothy Y Y Lai; Giovanni Staurenghi; Paolo Lanzetta; Frank G Holz; Shiao Hui Melissa Liew; Sabine Desset-Brethes; Harry Staines; Philip G Hykin Journal: Retina Date: 2018-08 Impact factor: 4.256